The Business Case For Sustainability ― From Industry Resilience To Bottom Line Impact

In the biopharmaceutical industry, sustainability has evolved beyond a mere checkbox. Here is why, despite the effort needed to achieve ambitious goals, it is worthwhile to prioritize the planet and its people.

While protecting our planet's future is a strong incentive on its own, biopharma leaders also recognize that sustainability can have a positive impact on their businesses' bottom line. They understand that neglecting this critical issue can result in short- and long-term damage. With this shared understanding, companies are placing sustainability-focused goals at the core of their strategies. This approach is not only paving the way for future success but is also delivering immediate benefits.

For Cytiva's 2024 Global Biopharma Sustainability Review, data was collected from 800 pharma and biopharma executives across 18 countries to assess the industry's current progress in addressing sustainability challenges and the effects of prioritizing environmental initiatives. Continue reading to explore key insights from this survey on how sustainability efforts are influencing business outcomes.